

Federico Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1250366/publications.pdf>

Version: 2024-02-01

217
papers

6,476
citations

70961

41
h-index

88477

70
g-index

232
all docs

232
docs citations

232
times ranked

8665
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	1.3	4
2	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	1.3	1
3	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. <i>Viruses</i> , 2022, 14, 16.	1.5	3
4	Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. <i>HIV Medicine</i> , 2022, , .	1.0	5
5	Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1738-1740.	1.3	9
6	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	2.6	10
7	ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. <i>Clinical Microbiology and Infection</i> , 2022, 28, 812-822.	2.8	10
8	HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION.. <i>Actas Espanolas De Psiquiatria</i> , 2022, 50, 120-121.	0.1	0
9	The Antioxidant Activity of <i>Thymus serpyllum</i> Extract Protects against the Inflammatory State and Modulates Gut Dysbiosis in Diet-Induced Obesity in Mice. <i>Antioxidants</i> , 2022, 11, 1073.	2.2	8
10	Ten steps to eliminating hepatitis C in hospitals. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 481-483.	8.2	8
11	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	1.4	46
12	Intestinal anti-inflammatory effects of probiotics in DNBS-colitis via modulation of gut microbiota and microRNAs. <i>European Journal of Nutrition</i> , 2021, 60, 2537-2551.	1.8	18
13	Macrolide and fluoroquinolone resistance of <i>Mycoplasma genitalium</i> in southern Spain, 2018-2019. <i>Sexually Transmitted Infections</i> , 2021, 97, 8-10.	0.8	9
14	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	1.8	26
15	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021, 22, 218-224.	1.0	2
16	Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1343-1349.	1.3	3
17	Visión microbiológica del impacto de la pandemia de COVID-19 sobre la eliminación de la hepatitis C. ¿Estamos preparados?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 475-476.	0.3	2
18	Guide for the screening of HCV infection in Spain, 2020. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 527-528.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 119-126.	0.2	0
20	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.3	15
21	Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 878-886.	1.0	0
22	Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System. <i>Journal of Personalized Medicine</i> , 2021, 11, 475.	1.1	20
23	<i>Lactobacillus fermentum</i> CECT5716 ameliorates high fat diet-induced obesity in mice through modulation of gut microbiota dysbiosis. <i>Pharmacological Research</i> , 2021, 167, 105471.	3.1	43
24	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. <i>Nature</i> , 2021, 595, 707-712.	13.7	363
25	Let's leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world. <i>Journal of Hepatology</i> , 2021, 75, 224-226.	1.8	5
26	Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties. <i>Nutrients</i> , 2021, 13, 2595.	1.7	17
27	Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. <i>HIV Medicine</i> , 2021, 22, 674-681.	1.0	6
28	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2394-2399.	1.3	6
29	SHARED: An International Collaboration to Unravel Hepatitis C Resistance. <i>Viruses</i> , 2021, 13, 1580.	1.5	6
30	Pooling samples for hepatitis C RNA detection. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 608-609.	3.7	2
31	Comparison between Aptima® assays (Hologic) and the CoBAS® 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Mycoplasma genitalium</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1337-1342.	1.3	5
32	Impact of COVID-19 pandemic on hepatitis C elimination from the clinical microbiologist perspective. Are we ready?. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2021, 39, 475-476.	0.2	0
33	Highly accurate whole-genome imputation of SARS-CoV-2 from partial or low-quality sequences. <i>GigaScience</i> , 2021, 10, .	3.3	2
34	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 28-32.	0.3	15
35	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 127-131.	0.3	7
36	The prebiotic properties of <i>Hibiscus sabdariffa</i> extract contribute to the beneficial effects in diet-induced obesity in mice. <i>Food Research International</i> , 2020, 127, 108722.	2.9	30

#	ARTICLE	IF	CITATIONS
37	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020, 21, 128-134.	1.0	0
38	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , 2020, 21, 43-52.	1.0	12
39	Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 235-241.	1.3	13
40	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020, 38, 95.	0.2	0
41	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	1.3	13
42	GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). <i>Journal of Infection</i> , 2020, 81, 600-606.	1.7	6
43	Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey. <i>Lancet HIV</i> , 2020, 7, e772-e781.	2.1	51
44	Sample pooling for SARS-CoV-2 RT-PCR screening. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1687.e1-1687.e5.	2.8	35
45	The Beneficial Effects of <i>Lippia Citriodora</i> Extract on Diet-Induced Obesity in Mice Are Associated with Modulation in the Gut Microbiota Composition. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e2000005.	1.5	19
46	Reviewing the Composition of Vaginal Microbiota: Inclusion of Nutrition and Probiotic Factors in the Maintenance of Eubiosis. <i>Nutrients</i> , 2020, 12, 419.	1.7	75
47	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1294-1300.	1.3	12
48	Failure to bicitegravir and development of resistance mutations in an antiretroviral-experienced patient. <i>Antiviral Research</i> , 2020, 179, 104717.	1.9	18
49	Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy. <i>Sexually Transmitted Infections</i> , 2020, 96, 337-341.	0.8	2
50	In reply to: Confirmation of antibodies against hepatitis C virus by recombinant immunoblot: Is it really an improvement to abandon it?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 95.	0.3	2
51	Posición actual de la carga viral frente a la determinación de antígeno core del virus de la hepatitis C. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020, 38, 12-18.	0.3	4
52	Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission. <i>PLoS ONE</i> , 2020, 15, e0233528.	1.1	10
53	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Española De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.1	20
54	Hepatitis E 3ra Genotype Infection in People Living With HIV in Spain. <i>Frontiers in Microbiology</i> , 2020, 11, 564486.	1.5	10

#	ARTICLE	IF	CITATIONS
55	Bacteria associated with periodontal disease are also increased in health. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2020, 25, e745-e751.	0.7	6
56	Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 515-519.	0.1	8
57	Unusual case report of skin infection by <i>Paenibacillus timonensis</i> . <i>Revista Espanola De Quimioterapia</i> , 2020, 33, 139-140.	0.5	5
58	Title is missing!. , 2020, 15, e0233528.		0
59	Title is missing!. , 2020, 15, e0233528.		0
60	Title is missing!. , 2020, 15, e0233528.		0
61	Title is missing!. , 2020, 15, e0233528.		0
62	Title is missing!. , 2020, 15, e0233528.		0
63	THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment. <i>Journal of Hepatology</i> , 2019, 70, e219-e220.	1.8	0
64	<i>Lactobacillus reuteri</i> V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study. <i>Nutrients</i> , 2019, 11, 1761.	1.7	53
65	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019, 71, 876-888.	1.8	13
66	Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions. <i>Frontiers in Microbiology</i> , 2019, 10, 370.	1.5	9
67	Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. <i>Journal of Hepatology</i> , 2019, 71, 1270-1272.	1.8	7
68	The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 634-641.	0.2	2
69	The metabolic and vascular protective effects of olive (<i>Olea europaea</i> L.) leaf extract in diet-induced obesity in mice are related to the amelioration of gut microbiota dysbiosis and to its immunomodulatory properties. <i>Pharmacological Research</i> , 2019, 150, 104487.	3.1	59
70	THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort. <i>Journal of Hepatology</i> , 2019, 70, e236.	1.8	0
71	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2019, 42, 579-592.	0.0	2
72	Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. <i>PLoS ONE</i> , 2019, 14, e0221231.	1.1	11

#	ARTICLE	IF	CITATIONS
73	Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections. PLoS ONE, 2019, 14, e0222439.	1.1	22
74	FRI-229-Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective. Journal of Hepatology, 2019, 70, e495-e496.	1.8	1
75	Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible. Open Forum Infectious Diseases, 2019, 6, ofy332.	0.4	23
76	Diagnóstico tradicional versus diagnóstico en un solo paso del virus de la hepatitis C. Estudio piloto en 2 centros asistenciales. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 348-349.	0.3	11
77	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. Annals of Hepatology, 2019, 18, 236-239.	0.6	3
78	Infection with multiple hepatitis C virus genotypes detected using commercial tests should be confirmed using next generation sequencing. Scientific Reports, 2019, 9, 9264.	1.6	6
79	Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study. BMC Cancer, 2019, 19, 495.	1.1	75
80	G2-S16 sulfonate dendrimer as new therapy for treatment failure in HIV-1 entry inhibitors. Nanomedicine, 2019, 14, 1095-1107.	1.7	15
81	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. Journal of Antimicrobial Chemotherapy, 2019, 74, 1693-1700.	1.3	19
82	Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. Journal of Hepatology, 2019, 71, 45-51.	1.8	45
83	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus coinfected individuals in EuroSIDA. HIV Medicine, 2019, 20, 264-273.	1.0	9
84	Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota. Nutrients, 2019, 11, 337.	1.7	64
85	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. Journal of Antimicrobial Chemotherapy, 2019, 74, 1357-1362.	1.3	16
86	El diagnóstico de la infección por el virus de la hepatitis C en España: una oportunidad para mejorar. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 231-238.	0.3	19
87	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015. Enfermedades Infecciosas Y Microbiología Clínica (English Ed) Tj ETQqJ2l 0.784314 rgB		
88	Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 314-320.	0.9	6
89	Long-term virological suppression on first-line efavirenz+tenofovir+emtricitabine/lamivudine for HIV-1. Aids, 2019, 33, 745-751.	1.0	3
90	E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection. Aids, 2019, 33, 1613-1617.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Effect of daily consumption of extra virgin olive oil on the lipid profile and microbiota of HIV-infected patients over 50 years of age. <i>Medicine (United States)</i> , 2019, 98, e17528.	0.4	14
92	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 195-202.	0.3	9
93	The Immunomodulatory Properties of Propylpropane Thiosulfonate Contribute to its Intestinal Anti-inflammatory Effect in Experimental Colitis. <i>Molecular Nutrition and Food Research</i> , 2019, 63, e1800653.	1.5	40
94	Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 143-155.	4.6	255
95	La simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectiva. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 634-641.	0.3	12
96	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019, 42, 579-592.	0.2	25
97	Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. <i>Eurosurveillance</i> , 2019, 24, .	3.9	14
98	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Española De Enfermedades Digestivas</i> , 2019, 112, 64-70.	0.1	4
99	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Española De Enfermedades Digestivas</i> , 2019, 111, 862-873.	0.1	12
100	Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 580-587.	0.3	4
101	Spatiotemporal Characteristics of the HIV-1 CRF02_AG/CRF63_02A1 Epidemic in Russia and Central Asia. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 415-420.	0.5	19
102	Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. <i>Drug Resistance Updates</i> , 2018, 37, 17-39.	6.5	155
103	A safe and easy method for building consensus HIV sequences from 454 massively parallel sequencing data. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2018, 36, 91-94.	0.2	0
104	Continued propagation of the CRF19_cpx variant among HIV-positive MSM patients in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1031-1038.	1.3	12
105	Spanish and Catalan translation, cultural adaptation and validation of the Picker Patient Experience Questionnaire-15. <i>Journal of Healthcare Quality Research</i> , 2018, 33, 10-17.	0.2	4
106	Validación de un método seguro y sencillo para la elaboración de secuencias consenso del virus de la inmunodeficiencia humana a partir de los datos de secuenciación masiva 454. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 91-94.	0.3	0
107	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. <i>Clinical Microbiology and Infection</i> , 2018, 24, 540-545.	2.8	13
108	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. <i>Aids</i> , 2018, 32, 327-335.	1.0	13

#	ARTICLE	IF	CITATIONS
109	PMD120 - HEALTHCARE OUTCOMES OF ONE-STEP DIAGNOSIS IN PATIENTS WITH CHRONIC HEPATITIS C. Value in Health, 2018, 21, S263.	0.1	0
110	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication, 2018, 4, 179-181.	0.3	9
111	Analysis of the quality of patient therapeutic education and information in a high complexity reference hospital. Journal of Healthcare Quality Research, 2018, 33, 343-351.	0.2	5
112	Guía de tratamiento de la infección por virus de la hepatitis C. Asociación Española para el Estudio del Hígado (AEEH). Gastroenterología Y Hepatología, 2018, 41, 597-608.	0.2	15
113	Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers. World Journal of Gastroenterology, 2018, 24, 5223-5233.	1.4	26
114	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. Scientific Reports, 2018, 8, 14905.	1.6	4
115	Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution. British Journal of Pharmacology, 2018, 175, 4353-4370.	2.7	36
116	Intestinal anti-inflammatory effect of the probiotic <i>Saccharomyces boulardii</i> in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. Journal of Nutritional Biochemistry, 2018, 61, 129-139.	1.9	98
117	<i>Lactobacillus fermentum</i> Improves Tacrolimus-Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling. Molecular Nutrition and Food Research, 2018, 62, e1800033.	1.5	71
118	Diagnosis of hepatitis C virus infection in Spain. On the correct side of the road?. Journal of Hepatology, 2018, 68, S173-S174.	1.8	2
119	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. American Journal of Gastroenterology, 2018, 113, 1639-1648.	0.2	72
120	Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelling by phylogenetic analysis. PLoS ONE, 2018, 13, e0201268.	1.1	14
121	The Administration of <i>Escherichia coli</i> Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice. Frontiers in Pharmacology, 2018, 9, 468.	1.6	68
122	Immunomodulatory tetracyclines ameliorate DNBS-colitis: Impact on microRNA expression and microbiota composition. Biochemical Pharmacology, 2018, 155, 524-536.	2.0	14
123	Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infectious Diseases, 2018, 18, 251.	1.3	33
124	The efficiency of several one-step testing strategies for the diagnosis of hepatitis C. Revista Española De Enfermedades Digestivas, 2018, 111, 10-16.	0.1	9
125	The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. Journal of Virus Eradication, 2018, 4, 179-181.	0.3	5
126	Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the Tj ETQq0 0,0rgBT /Overlock 10	1.0	28

#	ARTICLE	IF	CITATIONS
127	One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents. <i>Environmental Microbiology</i> , 2017, 19, 1536-1551.	1.8	54
128	Real life retreatment of patients failing DAAs in Spain: data from the HCVREsp cohort. <i>Journal of Hepatology</i> , 2017, 66, S313.	1.8	1
129	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	2.7	28
130	Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. <i>HIV Medicine</i> , 2017, 18, 482-489.	1.0	1
131	Differential intestinal anti-inflammatory effects of <i>Lactobacillus fermentum</i> and <i>Lactobacillus salivarius</i> in DSS mouse colitis: impact on microRNAs expression and microbiota composition. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1700144.	1.5	135
132	Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 29-34.	0.8	14
133	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	1.0	45
134	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861.	1.3	12
135	High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach. <i>PLoS ONE</i> , 2017, 12, e0186928.	1.1	7
136	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
137	The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. <i>PLoS ONE</i> , 2017, 12, e0175564.	1.1	5
138	Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?. <i>Germes</i> , 2017, 7, 40-44.	0.5	16
139	Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing. <i>AIDS Reviews</i> , 2017, 19, 231-238.	0.5	4
140	Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure. <i>BMC Infectious Diseases</i> , 2016, 16, 197.	1.3	4
141	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. <i>Journal of Infection</i> , 2016, 72, 587-596.	1.7	60
142	Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1975-1981.	1.3	43
143	New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. <i>Journal of Clinical Virology</i> , 2016, 81, 82-89.	1.6	60
144	Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1948-1953.	1.3	61

#	ARTICLE	IF	CITATIONS
145	Executive summary of the consensus document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 122-131.	0.3	2
146	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
147	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	2.9	135
148	Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy—Experienced Patients in Europe (CAPRE). <i>Journal of Infectious Diseases</i> , 2016, 213, 39-48.	1.9	28
149	Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. <i>PLoS ONE</i> , 2016, 11, e0153754.	1.1	34
150	Phylogenetic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain. <i>PLoS ONE</i> , 2016, 11, e0168099.	1.1	7
151	Pyrosequencing Analysis Reveals Changes in Intestinal Microbiota of Healthy Adults Who Received a Daily Dose of Immunomodulatory Probiotic Strains. <i>Nutrients</i> , 2015, 7, 3999-4015.	1.7	49
152	Primary resistance to integrase strand-transfer inhibitors in Europe: Table 1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2885-2888.	1.3	61
153	Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 544-556.	0.3	10
154	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015, 71, 571-577.	1.7	42
155	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007–2012). <i>Clinical Microbiology and Infection</i> , 2015, 21, 105.e1-105.e5.	2.8	11
156	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. <i>Clinical Microbiology and Infection</i> , 2015, 21, 104.e1-104.e5.	2.8	7
157	Clinically Relevant Transmitted Drug Resistance to First Line Antiretroviral Drugs and Implications for Recommendations. <i>PLoS ONE</i> , 2014, 9, e90710.	1.1	17
158	Use of deep sequencing data for routine analysis of HIV resistance in newly diagnosed patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19748.	1.2	3
159	Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. <i>Clinical Infectious Diseases</i> , 2014, 59, 578-588.	2.9	38
160	Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes. <i>Aids</i> , 2014, 28, 1835-1837.	1.0	6
161	Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19520.	1.2	2
162	A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. <i>Science Translational Medicine</i> , 2013, 5, 166ra2.	5.8	193

#	ARTICLE	IF	CITATIONS
163	Predictors of CD4+ T-Cell Counts of HIV Type 1â€“Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
164	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	1.3	9
165	Quantification of Viral Loads Lower than 50 Copies per Milliliter by Use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, Version 2.0, Can Predict the Likelihood of Subsequent Virological Rebound to >50 Copies per Milliliter. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1555-1557.	1.8	24
166	Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. <i>Aids</i> , 2013, 27, 1219-1229.	1.0	49
167	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	1.4	62
168	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 156-164.	0.5	18
169	Most HIV Type 1 Non-B Infections in the Spanish Cohort of Antiretroviral Treatment-Naïve HIV-Infected Patients (CoRIS) Are Due to Recombinant Viruses. <i>Journal of Clinical Microbiology</i> , 2012, 50, 407-413.	1.8	41
170	Analysis of transmitted drug resistance in Spain in the years 2007â€“2010 documents a decline in mutations to the non-nucleoside drug class. <i>Clinical Microbiology and Infection</i> , 2012, 18, E485-E490.	2.8	26
171	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	4.6	41
172	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	0.9	7
173	Improving Clinical Laboratory Efficiency: Introduction of Systems for the Diagnosis and Monitoring of HIV Infection. <i>The Open Virology Journal</i> , 2012, 5, 135-143.	1.8	7
174	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	0.9	13
175	Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists. <i>AIDS Reviews</i> , 2012, 14, 208-17.	0.5	35
176	The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens. <i>Journal of Virology</i> , 2011, 85, 11468-11478.	1.5	63
177	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 394-407.	4.6	218
178	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
179	Predicting antiretroviral drug resistance from the latest or the cumulative genotype. <i>Antiviral Therapy</i> , 2011, 16, 373-381.	0.6	13
180	Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS). <i>Antiviral Research</i> , 2011, 89, 19-25.	1.9	20

#	ARTICLE	IF	CITATIONS
181	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). <i>Antiviral Research</i> , 2011, 91, 150-153.	1.9	37
182	O5-6.1 Immunological response to hepatitis B vaccination in HIV infected patients: associated factors. <i>Journal of Epidemiology and Community Health</i> , 2011, 65, A56-A56.	2.0	0
183	Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects. <i>PLoS ONE</i> , 2011, 6, e19461.	1.1	45
184	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	1.0	13
185	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	4.3	42
186	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. <i>Antiviral Research</i> , 2010, 88, 281-286.	1.9	28
187	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	1.4	8
188	Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. <i>AIDS Reviews</i> , 2010, 12, 135-48.	0.5	42
189	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010.	1.3	64
190	Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767.	2.5	50
191	HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. <i>AIDS Reviews</i> , 2009, 11, 39-51.	0.5	16
192	Clinical spectrum of fever of intermediate duration in the south of Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 993-995.	1.3	19
193	Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in South Eastern Spain (2005-2007). Detection of Minority Viral Quasispecies. <i>International Journal of Infectious Diseases</i> , 2008, 12, e157-e158.	1.5	1
194	Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891.	1.8	98
195	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	1.3	76
196	Levels of HSP70 in HIV+ patients in different viroimmunological states. <i>Journal of Medical Virology</i> , 2006, 78, 318-323.	2.5	5
197	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.	2.9	53
198	Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.	2.9	31

#	ARTICLE	IF	CITATIONS
199	Retrospective analysis of antiretroviral HIV treatment success based on medical history or guided by the reverse hybridisation LiPA HIV genotyping system. <i>Journal of Medical Virology</i> , 2004, 73, 151-157.	2.5	2
200	Introduction of HIV type 1 non-B subtypes into Eastern Andalusia through immigration. <i>Journal of Medical Virology</i> , 2003, 70, 10-13.	2.5	10
201	Study of different systems for interpreting results of genotypic antiretroviral drug resistance tests. <i>Antiviral Therapy</i> , 2003, 8, 251-2.	0.6	1
202	Study of Different Systems for Interpreting Results of Genotypic Antiretroviral Drug Resistance Tests. <i>Antiviral Therapy</i> , 2003, 8, 251-252.	0.6	7
203	ACCUMULATION OF METALS IN AUTOPSY TISSUES OF SUBJECTS LIVING IN TARRAGONA COUNTY, SPAIN. <i>Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering</i> , 2001, 36, 1767-1786.	0.9	99
204	The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. <i>Aids</i> , 2001, 15, F29-F40.	1.0	160
205	Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 Å– 106/l. <i>Aids</i> , 2001, 15, 131-133.	1.0	8
206	Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1???Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 26-35.	0.9	7
207	Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. <i>Aids</i> , 2000, 14, 2485-2494.	1.0	39
208	Residual Low-Level Viral Replication Could Explain Discrepancies between Viral Load and CD4+ Cell Response in Human Immunodeficiency Virusâ€™Infected Patients Receiving Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2000, 30, 392-394.	2.9	30
209	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 1999, 179, 475-483.	1.9	23
210	Detection of hepatitis A virus in wastewater. <i>Environmental Toxicology</i> , 1999, 14, 391-396.	2.1	7
211	Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication. <i>Aids</i> , 1999, 13, 1491-1496.	1.0	62
212	Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. <i>Aids</i> , 1999, 13, F79-F86.	1.0	235
213	A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. <i>Aids</i> , 1999, 13, 2377-2388.	1.0	42
214	Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 Å– 106/l. <i>Aids</i> , 1997, 11, 53-57.	1.0	39
215	Relationship between viral genotype and viral load in patients with chronic hepatitis C. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 884-887.	1.3	9
216	Serum hepatitis B virus DNA detection with S- and C-region-directed probes. <i>Journal of Medical Microbiology</i> , 1993, 39, 473-475.	0.7	4

#	ARTICLE	IF	CITATIONS
217	Polyarteritis nodosa confined to calf muscles. Journal of Rheumatology, 1992, 19, 303-5.	1.0	27